Regents' Professor (part time), Leon H. Charbonnier Endowed Chair
Department of Cellular Biology and Anatomy
Senior Research Career Scientist, Director of Research Development
Charlie Norwood VA Medical Center
Office: R&E Building, CB1124
Phone: 706-721-2825
Fax: 706-721-6120
Email: zdong@augusta.edu
Lab Personnel:
Qingqing Wei, PhD, Asst Professor
Man J. Livingston, MD/PhD, Asst Res Scientist
Shixuan Wang, MD/PhD, Asst Res Scientist
Guie Dong, Research Associate
Zhengwei Ma, MD/PhD, Research Associate
Zhixia Song, MD/PhD, Visiting Researcher
Jiefu Zhu, MD, Visiting Graduate Student
Xiaohong Xiang, MD, Visiting Graduate Student
Mengru Zeng, MD, Visiting Graduate Student
Yu Yan, Visiting Graduate Student
Zhao, Xingchen, MD, Visiting Researcher
1985-1989 B.Sc. | Microbiology, Fudan University, Shanghai, P.R. China | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1989-1994 PhD | Physiology, Shanghai Institute of Physiology, Chinese Academy of Sciences |
1994-1998 | University of Texas Health Science Center (UTHSC) at San Antonio |
2000 | Lyndon B. Johnson Research Award | American Heart Association | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2001 | Lyndon B. Johnson Research Award | American Society of Nephrology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2001 | Patricia W. Robinson Young Investigator | National Kidney Foundation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2004 | Career Development Award | VISN 7, Department of Veterans Affairs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2005 | Distinguished Faculty Award (Basic Science) | School of Medicine, MCG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2005 | Distinguished Research Award | School of Graduate Studies, MCG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2008 | Research Career Scientist Award | Department of Veterans Affairs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2011 | Regents’ Professorship | University System of Georgia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2011 | Regents’ Professorship | University System of Georgia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2013 | Senior Research Career Scientist | Department of Veterans Affairs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2016 | Leon H. Charbonnier Endowed Chair | Augusta University |
JASN - Journal of American Society of Nephrology
Kidney International
American Journal of Physiology-Renal Physiology
American Journal of Physiology-Cell Physiology
Bioinorganic Chemistry and Applications
World Journal of Biological Chemistry
Journal of Geriatric Cardiology
Frontiers in Non-coding RNA
Frontiers in Translational Physiology
Journal of Nephrology and Renal Transplantation
International Journal of Experimental and Clinical Pathology
Open Pathology Journal
1) Essentials of Apoptosis: A Guide for Basic and Clinical Research
Editors: Xiao-Ming Yin and Zheng Dong
1st edition, Humana Press, 259 pages.
ISBN: 978-1-59259-361-3, 2003
2nd edition, Humana Press, 707 pages.
ISBN: 978-1-60327-380-0, 2009
http://www.springer.com/us/book/9781603273800
2) Cell Death in Biology and Diseases
Series Editor: Xiao-Ming Yin and Zheng Dong
Publisher: Springer
NIH: | Chartered Member | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PBKD Study Section 2012-2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ad hoc member: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PBKD Study Section 2006.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PBKD Study Section 2007.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PBKD Study Section 2008.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PBKD Study Section 2010.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PBKD Study Section 2011.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PBKD Study Section 2011.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PCD Study Section 2002.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CSD Study Section 2006.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-G 02, 2009.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-A 58 2009.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-K11 2009.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-G 03, 2009.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-G11, 2010.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-A 05, 2011.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 OBT-Z 50, 2013.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZDK1 GRB-N z(J6), 2013.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Botanical Dietary Supplement Research Centers (P50), 2014.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NCI Special panel ZCA1 RPRB-M (M5) 2016.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NCI Special panel ZCA1 SRB-1 (J1) R 2016.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-J (03) 2016.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-P (91) S 2017.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-P (02) M 2017.04 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 IDM-C 50 2017.07 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-P (04) 2017.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NCI Special panel ZCA1 SRB-A (M1) S 2018.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special panel ZRG1 DKUS-L (55) 2018.06 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VA: | Career Development Award Program 2006.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merit Review Panel for Nephrology 2010.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merit Review Panel for Nephrology 2010.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merit Review Panel for Nephrology 2011.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merit Review Panel for Nephrology 2011.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merit Review Panel for Nephrology 2012.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DoD: | U.S. Army Research Program 2004.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPSCoR IDeA Program 2006.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PRCRP 2011 D-Kidney Cancer panel 2011.11 |
China: | National Basic Research Program 2010.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1000 Talents Program for Young Scholars 2012.11; 2014 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changjiang Scholar Program 2013.5; 2015.5; 2016.7; 2017.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding Young Investigator Program 2012; 2015, 2016, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chinese National Science Foundation 2013-present | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
France: | French National Research Agency 2015.4, 2016.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Germany: | German Research Foundation 2013.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hong Kong: | Research Grant Council (RGC) of Hong Kong 2013.3; 2014.3, 2015.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Netherland: | Dutch Cancer Society 2012.7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dutch Kidney Foundation 2018.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Poland: | National Science Centre 2013.3, 2017.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Romania: | Romanian National Council for Scientific Research 2011.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Singapore: | Biomedical Research Council Program 2004.2, 2007.5, 2009.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Switzerland: | Swiss National Science Foundation 2016.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UK: | Cancer Research UK 2011.2, 2018.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Research Council (MRC) 2011.10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yorkshire Cancer Foundation 2013.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kidney Research UK 2013.1, 2014.1 |
Research Interests
The long-term goal of our research is to delineate the molecular mechanism of cell injury/death, its protection and subsequent regeneration. The current focus is the response of kidney and cancer cells/tissues to pathological conditions of hypoxia/ischemia, metabolic stress, and DNA damage. Our ongoing work includes the investigation of cell death, cell cycle, autophagy, mitochondria, and epigenetic regulation. We have thus far published over 240 full-length articles including 180 original papers and 60 invited reviews and commentaries, which have been cited for >15,000 times.
Contributions to Science
1. We have delineated the mitochondrial pathway of apoptosis in hypoxic/ischemic kidney injury, discovered the role of Bak in the regulation of mitochondrial dynamics, and demonstrated the pathogenic role of mitochondrial dynamics disruption in disease. We showed that the mitochondrial pathway is centered on the regulation of outer membrane permeabilization by Bcl-2 family proteins, resulting in the release of apoptogenic factors, such as cytochrome c (Oncogene 1998; JBC 1998, 2001, 2003, 2004, 2007; AJP-renal 2004, 2006; JASN 2006; KI 2007; JBC 2003, 2008). Our recent work further revealed a striking change of mitochondrial dynamics during cell injury and stress leading to mitochondrial fragmentation. We also demonstrated the first evidence for the involvement of mitochondrial dynamics in disease. We have further discovered a novel role of Bak in mitochondrial fragmentation and damage under cell stress and disease conditions. These studies have been published in 41 research articles and have been cited for ~4000 times. We have also contributed authoritative reviews in this field (eg. Zhan M. et. al. Kidney Int 2013; Linkermann et al. JASN 2014).
Representative Original Publications:
a. Brooks C, Wei Q, Feng L, Dong G, Tao Y, Mei L, Xie Z, Dong Z. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with Mitofusins. Proceedings of National Academy of Sciences (USA) 104: 11649-11654, 2007. PMCID: PMC1913853 (Highlighted by Faculty 1000; with news report)
b. Brooks C, Wei Q, Cho S, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. Journal of Clinical Investigation 119: 1275-85, 2009. PMCID: PMC2673870 (with news report)
c. Jiang M, Pabla N, Murphy RF, Yang T, Yin XM, Degenhardt K, White E. Dong Z. Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak activation. Journal of Biological Chemistry 282:2636-45, 2007. PMCID: PMC2859169
d. Wei Q, Dong G, Chen J, Ramesh G, Dong Z. Role of Bax and Bak in ischemic acute kidney injury shown by global and proximal tubule-specific knockout mouse models. Kidney International 84:138-48, 2013. PMCID: PMC3686831
e. Wei Q, Sun H, Liu Y, Liu P, M.J. Livingston, Wang J, Liang M, Huo Y, Nahman S, Mei C, Dong Z. miR-668 is induced via HIF-1 in ischemic acute kidney injury to repress MTP18 for mitochondrial dynamics and cell survival. Journal of Clinical Investigation (in press).
2. We have unveiled a rapid DNA damage response during cisplatin-induced nephrotoxicity and have further determined its pathogenic role. These findings have been verified by other investigators, leading to the recognition of the DNA damage response mediated by ATR/Chk2/p53 as an important pathogenic mechanism in cisplatin nephrotoxicity. The studies have been published in 31 research articles and have been cited for ~3000 times. We have also contributed authoritative reviews in this field (eg. Pabla N et al. Kidney Int 2008; Jiang M et al. JPET 2008; Yang Y et al. Arch Toxicol 2014; Zhu S et al. Arch Toxicol 2015).
Representative Original Publications:
a. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25:4056-66, 2006.
b. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. Journal of Biological Chemistry 283: 6572 – 6583, 2008. PMID: 18162465 (Highlighted by Faculty 1000)
c. Pabla N, Ma Z, McIlhatton MA, Fishel R, Dong Z. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. Journal of Biological Chemistry 286:10411-8. 2011. PMCID: 3060494
d. Zhang D, Liu Y, Wei Q, Huo Y, Liu K, Liu F, Dong Z. Tubular p53 regulates multiple genes to mediate acute kidney injury Journal of American Society of Nephrology 25(10):2278-89, 2014 (Highlighted on journal cover)
3. We have demonstrated the first evidence of autophagy in acute kidney injury and have further established its role in kidney injury and repair. This line of work has been extended by other investigators to show the role and regulation of autophagy in other renal diseases, suggesting a therapeutic approach for kidney protection. The studies have been published in 21 research articles and have been cited for 2000 times. , We have also contributed authoritative reviews in this field (Periyasamy-Thandavan Set. al. AJP-Renal 2009; Huber et al. Autophagy 2012; Livingston et al. Seminar in Nephrol 2014).
Representative Original Publications:
a. Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin X, Dong Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney International 74, 631–640, 2008. PMID: 18509315. (Highlighted by Editorial: Kidney Int 74, 555-7)
b. Jiang M, Liu K, Luo J, Dong Z. Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. American Journal of Pathology 176:1181-92, 2010. PMCID: PMC2832141 (Highlighted by Kidney Int 77, 563–564)
c. Jiang M, Wei Q, Dong G, Komatsu M, Su Y, Dong Z. Autophagy in proximal tubules protects against acute kidney injury. Kidney International 82: 1271-1283, 2012. (highlighted by Editorial: Kidney Int 82: 1250-3; also highlighted by Nature Rev Nephrol)
d. Livingston M, Ding H, Huang S, Hill J, Yin X, Dong Z. Persistent activation of autophagy in kidney tubular cells promotes renal interstitial fibrosis during unilateral ureteral obstruction. Autophagy 12(6):976-98, 2016
e. Zhang D, Pan J, Xiang X, Liu Y, Dong G, Livingston MJ, Chen JK, Yin XM, Dong Z. Protein Kinase Cδ Suppresses Autophagy to Induce Kidney Cell Apoptosis in Cisplatin Nephrotoxicity. Journal of American Society of Nephrology 28:1131-44, 2017.(Selected by Autophagy for commentary)
4. We have reported the first evidence of microRNA and DNA methylation as epigenetic mechanisms in ischemic and cisplatin nephrotoxic kidney injury. We have subsequently delineated the regulation of specific microRNAs in kidney injury, protection, and repair. These studies, published in 19 research articles, have gained new insights into the pathogenesis of acute kidney injury and recovery, and have suggested novel therapeutic strategies by targeting epigenetics. We have also contributed several reviews (Bhatt et al. AJP-Renal 2011; Wei Q et al. IUBMB Life 2013; Kidney Int 2015; Nature Rev Nephol 2018).
Representative Original Publications:
a. Wei Q, Bhatt K, He H, Mi Q, Haase VH, Dong Z. Targeted deletion of Dicer from proximal tubules protects against ischemic acute kidney injury. Journal of American Society of Nephrology 21: 756-761, 2010. PMCID: PMC2865746. (Highlighted on journal cover)
b. Bhatt K, Wei Q, Pabla N, Dong G, Mi Q, Mei C, Dong Z. microRNA-687 induced by HIF-1 targets PTEN in renal ischemia-reperfusion injury. Journal of American Society of Nephrology 26:1588-96. 2015 (Highlighted by Editorial: JASN 26, 1478-80)
c. Wei Q, Liu Y, Liu P, Hao J, Liang M, Mi Q, Chen J, Dong Z. MicroRNA-489 is induced via HIF-1 to protect against ischemic kidney injury. Journal of American Society of Nephrology 27(9):2784-96. 2016
d. Hao J, Lou Q, Wei Q, Mei S, Li L, Wu G, Mi QS, Mei C, Dong Z. MicroRNA-375 Is Induced in Cisplatin Nephrotoxicity to Repress Hepatocyte Nuclear Factor 1-β. Journal of Biological Chemistry 292:4571-4582, 2017
e. Guo C, Pei L, Xiao X, Wei Q, Chen JK, Ding HF, Huang S, Fan G, Shi H, Dong Z. DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8. Kidney International 92(5):1194-1205, 2017
5. We have delineated the differential PKCδ signaling pathways in malignant and normal tissues suggesting an effective approach for kidney protection during cisplatin chemotherapy. We have discovered a new alternatively spliced checkpoint kinase-1 (named Chk1-S) as a novel regulator of cell cycle and DNA damage response. Our latest work has discovered the novel interaction between Intu and STAT1 in the regulation of cell death and cilia in kidney injury.
Representative Original Publications:
a. Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing R, Dong Z. PKCδ is a novel regulator of cisplatin nephrotoxicity and effective target for renoprotection during cancer therapy. Journal of Clinical Investigation 121: 2709-2722, 2011. PMCID: PMC3223835 (news report)
b. Pabla N, Bhatt K, Dong Z. Chk1-S is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Proceedings of National Academy of Sciences (USA) 109: 197-202, 2012. PMCID: PMC3252905 (news report)
c. Wang S, Livingston M, Su Y, Dong Z. Reciprocal regulation of cilia and autophagy via MTOR and proteasome pathways. Autophagy 11:607-616, 2015
d. Wang S, Liu A, Wu G, Ding H, Huang S, Dong Z. The CPLANE protein Intu protects kidneys from ischemia-reperfusion injury by targeting STAT1 for degradation. Nature Communications 2018 Mar 26; 9(1):1234. PMCID: PMC5964315
Confocal image of mitochondria. In control cells, mitochondria are elongated and filamentous. After injury, mitochondria are fragmented into short rods or spheres. The morphological change contributes to mitochondrial damage and apoptosis (Brooks et al. PNAS 104: 11649-11654, 2007. JCI 119:1275-85, 2009).
Ovarian cancer xenografts were established in nude mice, which were then treated with
cisplatin with or without Rottlerin, a PKCδ inhibitor. In this and other tumor models,
Rottlerin and relevant protect protect kidneys and enhance cancer therapy effect during
cisplatin treatment. (Pabla et al. JCI 2011).
Approaches:
Gene cloning, transfection, expression, knockout (antisense and RNAi), promoter assay, genotyping, Northern/Southern blot, microRNA analysis, immunoblotting, immunoprecipitation, immunofluorescence, immunohistochemistry and light/fluorescence/confocal microscopy. In vitro and in vivo experimental models, germline and tissue specific gene knockout mice.
Grant Support:
National Institutes of Health; Department of Veterans Affairs; American Heart Association
Representative Publications (2014-2018):
A. Original Studies
B. Invited Reviews/ Commentaries